Source: International Congress 2016 – IPF treatment I
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Luca Richeldi (Southampton, United Kingdom), Luca Richeldi, Arata Azuma, Moisés Selman, Wenbo Tang, Jorge Capapey, Susanne Stowasser, Vincent Cottin. Twenty-four week decline in forced vital capacity predicts mortality at week 52 in the INPULSIS® trials. Eur Respir J 2016; 48: Suppl. 60, 1814

Member's Comments

No comment yet.

Related content which might interest you: Real World experiences: Pirfenidone is well tolerated and reduces decline in FVC and TLCO at 9 months in IPF Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015 Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib Source: International Congress 2015 – Treatment of IPF Year: 2015 Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies Source: International Congress 2016 – New and old therapies for chronic lung diseases Year: 2016 Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Effect of anti-acid medication on reduction in FVC decline with nintedanib Source: International Congress 2015 – Treatment of IPF Year: 2015 Challenges in idiopathic pulmonary fibrosis trials: the point on end-points Source: Eur Respir Rev 2011; 20: 195-200 Year: 2011 The clinical significance of 24hr continuous monitoring of SpO2 during daily life in the patients with interstitial pneumonia Source: International Congress 2015 – IIPs: orphan Year: 2015 Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC)<50% treated with pirfenidone (PFD) in RECAP Source: International Congress 2016 – IPF treatment I Year: 2016 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 A six minute walking test (6MWT) derived index (O2-GAP) predicts mortality in IPF Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Source: Eur Respir Rev 2012; 21: 161-167 Year: 2012 Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Severe pulmonary hypertension in patients with emphysema but preserved FEV1: Prognosis and response to treatment Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer Source: Eur Respir J 2013; 41: 262-269 Year: 2013 Treatment of severe pulmonary hypertension in patients with interstitial lung disease: Results in 72 patients from the “HYPID” prospective study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Effect of an 8 week pulmonary rehabilitation program in patients with interstitial lung diseases in India. Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)? Year: 2018 Effect of baseline composite physiologic index on benefit of nintedanib in IPF Source: International Congress 2016 – IPF treatment I Year: 2016 Idiopathic pulmonary fibrosis: Gender differences in survival and functional decline. A retrospective study Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016